## João Costa Pessoa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4300857/publications.pdf

Version: 2024-02-01

197 papers 9,081 citations

28274 55 h-index 82 g-index

202 all docs 202 docs citations

times ranked

202

6370 citing authors

#	Article	IF	CITATIONS
1	Cellular ultrastructural studies and biological effects of copper complexes of phenanthroline derivatives. Annals of Medicine, 2024, 51, 36-36.	3.8	1
2	Copper(II) and oxidovanadium(IV) complexes of chromone Schiff bases as potential anticancer agents. Journal of Biological Inorganic Chemistry, 2022, 27, 89-109.	2.6	17
3	New phosphotetradecavanadate hybrids: crystal structure, DFT analysis, stability and binding interactions with bio-macromolecules. Dalton Transactions, 2022, , .	3.3	4
4	Binding of V <sup>IV</sup> O <sup>2+</sup> , V <sup>IV</sup> OL, V <sup>IV</sup> OL <sub>2</sub> and V <sup>V</sup> O <sub>2</sub> Moieties to Proteins: Xâ€ray/Theoretical Characterization and Biological Implications. Chemistry - A European Journal, 2022, 28, .	3.3	10
5	Liposomal Formulations of a New Zinc(II) Complex Exhibiting High Therapeutic Potential in a Murine Colon Cancer Model. International Journal of Molecular Sciences, 2022, 23, 6728.	4.1	10
6	New iron(III) anti-cancer aminobisphenolate/phenanthroline complexes: Enhancing their therapeutic potential using nanoliposomes. International Journal of Pharmaceutics, 2022, 623, 121925.	5.2	6
7	Solution chemical properties and anticancer potential of 8-hydroxyquinoline hydrazones and their oxidovanadium(IV) complexes. Journal of Inorganic Biochemistry, 2022, 235, 111932.	3.5	12
8	Cu( <scp>ii</scp> ) and V( <scp>iv</scp> )O complexes with tri- or tetradentate ligands based on (2-hydroxybenzyl)- <scp>I</scp> -alanines reveal promising anticancer therapeutic potential. Dalton Transactions, 2021, 50, 157-169.	3.3	17
9	Antimicrobial and antitumor activity of S-methyl dithiocarbazate Schiff base zinc(II) complexes. Journal of Inorganic Biochemistry, 2021, 216, 111331.	3.5	30
10	Misinterpretations in Evaluating Interactions of Vanadium Complexes with Proteins and Other Biological Targets. Inorganics, 2021, 9, 17.	2.7	41
11	Therapeutic potential of vanadium complexes with 1,10-phenanthroline ligands, quo vadis? Fate of complexes in cell media and cancer cells. Journal of Inorganic Biochemistry, 2021, 217, 111350.	3.5	38
12	Synthesis, characterization and DFT studies of novel –CH2– capped and non-capped salan complexes. Inorganica Chimica Acta, 2021, 519, 120265.	2.4	2
13	Enhancement of the Antioxidant and Antimicrobial Activities of Porphyran through Chemical Modification with Tyrosine Derivatives. Molecules, 2021, 26, 2916.	3.8	7
14	Binding of vanadium ions and complexes to proteins and enzymes in aqueous solution. Coordination Chemistry Reviews, 2021, 449, 214192.	18.8	40
15	New V <sup>IV</sup> , V <sup>IV</sup> O, V <sup>V</sup> O, and V <sup>V</sup> O <sub>2</sub> Systems: Exploring their Interconversion in Solution, Protein Interactions, and Cytotoxicity. Inorganic Chemistry, 2020, 59, 14042-14057.	4.0	46
16	-Phenylalanine derived tripodal vanadium complexes as catalysts for the asymmetric reductive coupling of benzaldehyde. Inorganica Chimica Acta, 2020, 510, 119727.	2.4	2
17	Copper Complexes with 1,10-Phenanthroline Derivatives: Underlying Factors Affecting Their Cytotoxicity. Inorganic Chemistry, 2020, 59, 9116-9134.	4.0	55
18	Unusual chemistry of Cu( <scp>ii</scp> ) salan complexes: synthesis, characterization and superoxide dismutase activity. New Journal of Chemistry, 2020, 44, 11457-11470.	2.8	7

#	Article	IF	CITATIONS
19	Exploring the therapeutic potential of Cu(II)-complexes with ligands derived from pyridoxal. Inorganica Chimica Acta, 2020, 507, 119558.	2.4	4
20	Trinuclear vanadium( <scp>iv</scp> ) and vanadium( <scp>v</scp> ) complexes derived from 2,4,6-triacetylphloroglucinol and study of their peroxidase mimicking activity. Dalton Transactions, 2020, 49, 2589-2609.	3.3	22
21	Interaction with Blood Proteins of a Ruthenium(II) Nitrofuryl Semicarbazone Complex: Effect on the Antitumoral Activity. Molecules, 2019, 24, 2861.	3.8	15
22	Exploring oxidovanadium( <scp>iv</scp> ) homoleptic complexes with 8-hydroxyquinoline derivatives as prospective antitrypanosomal agents. New Journal of Chemistry, 2019, 43, 17756-17773.	2.8	17
23	Naphthoylhydrazones: coordination to metal ions and biological screening. New Journal of Chemistry, 2019, 43, 17801-17818.	2.8	13
24	Cu(II) complexes derived from N-carboxymethyl and N-carboxyethyl amino acids as catalysts for asymmetric oxidative coupling of 2-naphthol. Molecular Catalysis, 2019, 475, 110480.	2.0	4
25	Experimental data on novel Fe(III)-complexes containing phenanthroline derivatives for their anticancer properties. Data in Brief, 2019, 27, 104548.	1.0	2
26	Exploring the cytotoxic activity of new phenanthroline salicylaldimine Zn(II) complexes. Journal of Inorganic Biochemistry, 2019, 198, 110727.	3.5	37
27	New thiosemicarbazide and dithiocarbazate based oxidovanadium( <scp>iv</scp> ) and dioxidovanadium( <scp>v</scp> ) complexes. Reactivity and catalytic potential. New Journal of Chemistry, 2019, 43, 17620-17635.	2.8	19
28	May iron(III) complexes containing phenanthroline derivatives as ligands be prospective anticancer agents?. European Journal of Medicinal Chemistry, 2019, 176, 492-512.	5.5	35
29	New ternary iron(iii) aminobisphenolate hydroxyquinoline complexes as potential therapeutic agents. Dalton Transactions, 2019, 48, 8702-8716.	3.3	17
30	New heterobimetallic ferrocenyl derivatives are promising antitrypanosomal agents. Dalton Transactions, 2019, 48, 7644-7658.	3.3	13
31	Lanthanide complexes with phenanthroline-based ligands: insights into cell death mechanisms obtained by microscopy techniques. Dalton Transactions, 2019, 48, 4611-4624.	3.3	38
32	Salan vs. salen metal complexes in catalysis and medicinal applications: Virtues and pitfalls. Coordination Chemistry Reviews, 2019, 388, 227-247.	18.8	115
33	New V <sup>IV</sup> O-complexes for oxidative desulfurization of refractory sulfur compounds in fuel: synthesis, structure, reactivity trend and mechanistic studies. Dalton Transactions, 2019, 48, 16687-16704.	3.3	10
34	Vanadium ionic species from degradation of Ti-6Al-4V metallic implants: In vitro cytotoxicity and speciation evaluation. Materials Science and Engineering C, 2019, 96, 730-739.	7.3	135
35	Cytotoxic activity and structural features of Ru(II)/phosphine/amino acid complexes. Journal of Inorganic Biochemistry, 2018, 182, 48-60.	3.5	21
36	Binding of vanadium to human serum transferrin - voltammetric and spectrometric studies. Journal of Inorganic Biochemistry, 2018, 180, 211-221.	3.5	24

#	Article	IF	CITATIONS
37	Synthesis, structure, solution behavior, reactivity and biological evaluation of oxidovanadium( <scp>iv</scp> / <scp>v</scp> ) thiosemicarbazone complexes. Dalton Transactions, 2018, 47, 11358-11374.	3.3	39
38	Photophysical properties and biological evaluation of a Zinc(II)-5-methyl-1H-pyrazole Schiff base complex. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2018, 204, 317-327.	3.9	9
39	Vanadium complexes supported on organic polymers as sustainable systems for catalytic oxidations. Inorganica Chimica Acta, 2017, 455, 415-428.	2.4	41
40	Ultrastructural features of cells following incubation with metal complexes using phenanthroline-based ligands: The influence of the metal center. Ultrastructural Pathology, 2017, 41, 128-129.	0.9	2
41	New Cu(II) complexes with pyrazolyl derived Schiff base ligands: Synthesis and biological evaluation. Journal of Inorganic Biochemistry, 2017, 174, 63-75.	3.5	54
42	Solution Behaviour and Catalytic Potential towards Oxidation of Dopamine by Oxidovanadium(V) Complexes of Tripodal Tetradentate Ligands. European Journal of Inorganic Chemistry, 2017, 2017, 3087-3099.	2.0	20
43	Heteroleptic oxidovanadium(IV) complexes of 2-hydroxynaphtylaldimine and polypyridyl ligands against Trypanosoma cruzi and prostate cancer cells. Journal of Inorganic Biochemistry, 2017, 175, 154-166.	3.5	30
44	Evaluation of the binding of four anti-tumor CasiopeÃnas® to human serum albumin. Journal of Inorganic Biochemistry, 2017, 175, 284-297.	3.5	36
45	Interaction of [V <sup>IV</sup> O(acac) <sub>2</sub> ] with Human Serum Transferrin and Albumin. Chemistry - an Asian Journal, 2017, 12, 2062-2084.	3.3	38
46	Synthesis, biological characterization and evaluation of molecular mechanisms of novel copper complexes as anticancer agents. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 218-234.	2.4	76
47	Evaluation of cellular uptake, cytotoxicity and cellular ultrastructural effects of heteroleptic oxidovanadium(IV) complexes of salicylaldimines and polypyridyl ligands. Journal of Inorganic Biochemistry, 2017, 166, 162-172.	3.5	46
48	Binding of Oxovanadium(IV) Complexes to Blood Serum Albumins. Journal of the Mexican Chemical Society, 2017, 57, .	0.6	2
49	Strecker degradation of amino acids promoted by a camphor-derived sulfonamide. Beilstein Journal of Organic Chemistry, 2016, 12, 732-744.	2.2	2
50	Validation data supporting the characterization of novel copper complexes as anticancer agents. Data in Brief, 2016, 9, 1160-1174.	1.0	3
51	Coordination ability and biological activity of a naringenin thiosemicarbazone. Journal of Inorganic Biochemistry, 2016, 165, 36-48.	3.5	20
52	Versatile Reactivity and Theoretical Evaluation of Mono- and Dinuclear Oxidovanadium(V) Compounds of Aroylazines: Electrogeneration of Mixed-Valence Divanadium(IV,V) Complexes. Inorganic Chemistry, 2016, 55, 8407-8421.	4.0	33
53	Synthesis, biological characterization and evaluation of molecular mechanisms of novel copper complexes as anticancer agents. Toxicology Letters, 2016, 258, S60.	0.8	1
54	Chemistry of Monomeric and Dinuclear Non-Oxido Vanadium(IV) and Oxidovanadium(V) Aroylazine Complexes: Exploring Solution Behavior. Inorganic Chemistry, 2016, 55, 1165-1182.	4.0	62

#	Article	IF	CITATIONS
55	Pinacol coupling of benzaldehydes mediated by titanium complexes displaying amine bis(phenolate) ligands. Journal of Molecular Catalysis A, 2016, 412, 107-116.	4.8	10
56	Expanding the family of heteroleptic oxidovanadium(IV) compounds with salicylaldehyde semicarbazones and polypyridyl ligands showing anti-Trypanosoma cruzi activity. Journal of Inorganic Biochemistry, 2015, 147, 116-125.	3.5	31
57	Vanadium compounds in medicine. Coordination Chemistry Reviews, 2015, 301-302, 24-48.	18.8	393
58	Vanadium(IV) and copper(II) complexes of salicylaldimines and aromatic heterocycles: Cytotoxicity, DNA binding and DNA cleavage properties. Journal of Inorganic Biochemistry, 2015, 147, 134-146.	3.5	93
59	The effect of phosphate on the nuclease activity of vanadium compounds. Journal of Inorganic Biochemistry, 2015, 147, 165-176.	3.5	8
60	Vanadium and proteins: Uptake, transport, structure, activity and function. Coordination Chemistry Reviews, 2015, 301-302, 49-86.	18.8	166
61	Thirty years through vanadium chemistry. Journal of Inorganic Biochemistry, 2015, 147, 4-24.	3.5	122
62	Oxygen activation by copper camphor complexes. Inorganic Chemistry Frontiers, 2015, 2, 1019-1028.	6.0	5
63	Vanadium( <scp>v</scp> ) complexes of a tripodal ligand, their characterisation and biological implications. Dalton Transactions, 2015, 44, 17736-17755.	3.3	59
64	Formation of an unusual pyridoxal derivative: Characterization of Cu(II), Ni(II) and Zn(II) complexes and evaluation of binding to DNA and to human serum albumin. Inorganica Chimica Acta, 2015, 426, 150-159.	2.4	20
65	Oxidovanadium( <scp>iv</scp> ) and dioxidovanadium( <scp>v</scp> ) complexes of hydrazones of 2-benzoylpyridine and their catalytic applications. Dalton Transactions, 2015, 44, 1211-1232.	3.3	43
66	Amino acid derived Cu <sup>II</sup> compounds as catalysts for asymmetric oxidative coupling of 2-naphthol. Dalton Transactions, 2015, 44, 1612-1626.	3.3	19
67	Cull–salan compounds: Synthesis, characterization and evaluation ofÂtheir potential as oxidation catalysts. Journal of Organometallic Chemistry, 2014, 760, 212-223.	1.8	30
68	New metal complexes of NNO tridentate ligands: Effect of metal center and co-ligand on biological activity. Inorganica Chimica Acta, 2014, 420, 39-46.	2.4	19
69	New insights on vanadium binding to human serum transferrin. Inorganica Chimica Acta, 2014, 420, 60-68.	2.4	51
70	Vanadium Complexes as Prospective Therapeutics: Structural Characterization of a V <sup>IV</sup> Lysozyme Adduct. European Journal of Inorganic Chemistry, 2014, 2014, 3293-3297.	2.0	53
71	New ternary bipyridine–terpyridine copper( <scp>ii</scp> ) complexes as self-activating chemical nucleases. RSC Advances, 2014, 4, 61363-61377.	3.6	25
72	Hydroxyquinoline derived vanadium(IV and V) and copper(II) complexes as potential anti-tuberculosis and anti-tumor agents. Journal of Inorganic Biochemistry, 2014, 141, 83-93.	3.5	125

#	Article	IF	CITATIONS
73	Polystyrene bound dioxidovanadium(V) complexes of 2-acetylpyridine derived ligands for catalytic oxidations. Inorganica Chimica Acta, 2014, 420, 24-38.	2.4	35
74	Interaction of vanadium(IV) with human serum apo-transferrin. Journal of Inorganic Biochemistry, 2013, 121, 187-195.	3.5	72
75	A novel VIVO–pyrimidinone complex: synthesis, solution speciation and human serum protein binding. Dalton Transactions, 2013, 42, 11841.	3.3	38
76	New polydentate Ru(III)-Salan complexes: Synthesis, characterization, anti-tumour activity and interaction with human serum proteins. Inorganica Chimica Acta, 2013, 394, 616-626.	2.4	31
77	An unusual half-open cubane-like tetranuclear copper(II) complex supported by both μ-alkoxo and μ3-hydroxo bridges: Structure, magnetic properties, EPR and DFT studies. Polyhedron, 2013, 53, 269-277.	2.2	11
78	Screening organometallic binuclear thiosemicarbazone ruthenium complexes as potential anti-tumour agents: cytotoxic activity and human serum albumin binding mechanism. Dalton Transactions, 2013, 42, 7131.	3.3	83
79	Synthesis, structure, magnetic properties and biological activity of supramolecular copper( <scp>ii</scp> ) and nickel( <scp>ii</scp> ) complexes with a Schiff base ligand derived from vitamin B <sub>6</sub> . Dalton Transactions, 2013, 42, 2594-2607.	3.3	60
80	Searching for Vanadiumâ€Based Prospective Agents against <i>Trypanosoma cruzi</i> : Oxidovanadium(IV) Compounds with Phenanthroline Derivatives as Ligands. Zeitschrift Fur Anorganische Und Allgemeine Chemie, 2013, 639, 1417-1425.	1.2	26
81	Vanadium complexes having [VO]2+, [VO]3+ and [VO2]+ cores with hydrazones of 2,6-diformyl-4-methylphenol: synthesis, characterization, reactivity, and catalytic potential. Dalton Transactions, 2013, 42, 11941.	3.3	90
82	New oxidovanadium(IV) N -acylhydrazone complexes: Promising antileishmanial and antitrypanosomal agents. European Journal of Medicinal Chemistry, 2013, 62, 20-27.	5.5	57
83	Oxidovanadium(IV) and dioxidovanadium(V) complexes of tridentate salicylaldehyde semicarbazones: Searching for prospective antitrypanosomal agents. Journal of Inorganic Biochemistry, 2013, 127, 150-160.	3.5	59
84	A new series of heteroleptic oxidovanadium(iv) compounds with phenanthroline-derived co-ligands: selective Trypanosoma cruzi growth inhibitors. Dalton Transactions, 2013, 42, 11900.	3.3	56
85	Spectroscopic studies of vanadium biosorption on different types of carbohydrate biomass. Canadian Journal of Chemistry, 2013, 91, 186-195.	1.1	9
86	Binding of VIVO2+ to the Fe binding sites of human serum transferrin. A theoretical study. Journal of Biological Inorganic Chemistry, 2013, 18, 803-813.	2.6	35
87	Analysis of the First Order and Slowly Varying Motions of an Axisymmetric Floating Body in Bichromatic Waves. Journal of Offshore Mechanics and Arctic Engineering, 2013, 135, .	1.2	4
88	[Rull(Î-5-C5H5)(bipy)(PPh3)]+, a promising large spectrum antitumor agent: Cytotoxic activity and interaction with human serum albumin. Journal of Inorganic Biochemistry, 2012, 117, 261-269.	3.5	72
89	Evaluation of the binding of oxovanadium(iv) to human serum albumin. Dalton Transactions, 2012, 41, 6477.	3.3	71
90	Synthesis, spectroscopic characterization, insulin-enhancment, and competitive DNA binding activity of a new Zn(ii) complex with a vitamin B6 derivative—a new fluorescence probe for Zn(ii). Dalton Transactions, 2012, 41, 5260.	3.3	52

#	Article	IF	CITATIONS
91	VIVO and Cull complexation by ligands based on pyridine nitrogen donors. Dalton Transactions, 2012, 41, 12824.	3.3	55
92	Amino Alcohol-Derived Reduced Schiff Base V <sup>IV</sup> O and V <sup>V</sup> Compounds as Catalysts for Asymmetric Sulfoxidation of Thioanisole with Hydrogen Peroxide. Inorganic Chemistry, 2012, 51, 11430-11449.	4.0	54
93	Spectroscopic and Structural Characterization of Noninnocent Mixed-Ligand Oxidovanadium(V) Complexes. European Journal of Inorganic Chemistry, 2012, 2012, 4846-4855.	2.0	12
94	Synthesis, Characterization, Catalytic and Antiamoebic Activity of Vanadium Complexes of Binucleating Bis(dibasic tridentate ONS donor) Ligand Systems. European Journal of Inorganic Chemistry, 2012, 2012, 2560-2577.	2.0	64
95	Synthesis, characterization, reactivity and catalytic activity of oxidovanadium(iv), oxidovanadium(v) and dioxidovanadium(v) complexes of benzimidazole modified ligands. Dalton Transactions, 2011, 40, 6968.	3.3	75
96	Oxidovanadium(IV) Schiff Base Complex Derived from Vitamin B <sub>6</sub> : Synthesis, Characterization, and Insulin Enhancing Properties. Inorganic Chemistry, 2011, 50, 4349-4361.	4.0	66
97	The speciation of vanadium in human serum. Coordination Chemistry Reviews, 2011, 255, 2218-2226.	18.8	99
98	Vanadium(IV) and â€(V) Complexes of Reduced Schiff Bases Derived from Aromatic <i>&gt;o</i> à€Hydroxyaldehydes and Tyrosine Derivatives. European Journal of Inorganic Chemistry, 2011, 2011, 694-708.	2.0	14
99	Chiral Diamine Bis(phenolate) Ti <sup>IV</sup> and Zr <sup>IV</sup> Complexes – Synthesis, Structures and Reactivity. European Journal of Inorganic Chemistry, 2011, 2011, 4277-4290.	2.0	20
100	Oxidovanadium(IV) Complexes of Tetradentate Ligands Encapsulated in Zeolite-Y as Catalysts for the Oxidation of Styrene, Cyclohexene and Methyl Phenyl Sulfide. European Journal of Inorganic Chemistry, 2011, 2011, 4846-4861.	2.0	39
101	Vanadium complexes immobilized on solid supports and their use as catalysts for oxidation and functionalization of alkanes and alkenes. Coordination Chemistry Reviews, 2011, 255, 2315-2344.	18.8	158
102	Polymer-bound metal complexes as catalysts: Synthesis, characterization, reactivity and catalytic activity in Eâ€"H bond activation. Journal of Organometallic Chemistry, 2011, 696, 244-254.	1.8	39
103	Vanadium polypyridyl compounds as potential antiparasitic and antitumoral agents: New achievements. Journal of Inorganic Biochemistry, 2011, 105, 303-312.	3 <b>.</b> 5	115
104	Copper(II) complexes with tridentate pyrazole-based ligands: synthesis, characterization, DNA cleavage activity and cytotoxicity. Journal of Inorganic Biochemistry, 2011, 105, 637-644.	3.5	77
105	Titanium(IV)â€"Salan Catalysts for Asymmetric Sulfoxidation with Hydrogen Peroxide. European Journal of Inorganic Chemistry, 2010, 2010, 5568-5578.	2.0	46
106	Transport of Therapeutic Vanadium and Ruthenium Complexes by Blood Plasma Components. Current Medicinal Chemistry, 2010, 17, 3701-3738.	2.4	187
107	Polymer-Bound Oxidovanadium(IV) and Dioxidovanadium(V) Complexes As Catalysts for the Oxidative Desulfurization of Model Fuel Diesel. Inorganic Chemistry, 2010, 49, 6586-6600.	4.0	109
108	Vanadium complexes having [VIVO]2+ and [V <sup>V</sup> O <sub>2</sub> ] <sup>+</sup> cores with binucleating dibasic tetradentate ligands: Synthesis, characterization, catalytic and antiamoebic activities. Dalton Transactions, 2010, 39, 1345-1360.	3.3	96

#	Article	IF	CITATIONS
109	Tricarbonyl M(I) (M = Re, 99mTc) complexes bearing acridine fluorophores: synthesis, characterization, DNA interaction studies and nuclear targeting. Organic and Biomolecular Chemistry, 2010, 8, 4104.	2.8	42
110	Vanadium Diaminebis(phenolate) Complexes: Syntheses, Structures, and Reactivity in Sulfoxidation Catalysis. Inorganic Chemistry, 2010, 49, 7452-7463.	4.0	82
111	Structural tuning and self-association of (arylimido)vanadium(V) compounds. Pure and Applied Chemistry, 2009, 81, 1187-1195.	1.9	8
112	Influence of polydentate ligands in the structure of dinuclear vanadium compounds. Pure and Applied Chemistry, 2009, 81, 1297-1311.	1.9	13
113	Vanadium-salen and -salan complexes: Characterization and application in oxygen-transfer reactions. Pure and Applied Chemistry, 2009, 81, 1279-1296.	1.9	58
114	Non-native states of cardosin A induced by acetonitrile: Activity modulation via polypeptide chains rearrangements. Journal of Molecular Catalysis B: Enzymatic, 2009, 61, 274-278.	1.8	2
115	Dinuclear Oxidovanadium(IV) and Dioxidovanadium(V) Complexes of 5,5′â€Methylenebis(dibasic) Tj ETQq1 1 (Activities. European Journal of Inorganic Chemistry, 2009, 2009, 5377-5390.	0.784314 2.0	rgBT /Overlo
116	Design of vanadium mixed-ligand complexes as potential anti-protozoa agents. Journal of Inorganic Biochemistry, 2009, 103, 609-616.	3.5	92
117	Vanadium compounds as therapeutic agents: Some chemical and biochemical studies. Journal of Inorganic Biochemistry, 2009, 103, 601-608.	3.5	68
118	DNA cleavage activity of VIVO(acac)2 and derivatives. Journal of Inorganic Biochemistry, 2009, 103, 622-632.	3.5	59
119	Preface: 6th International Vanadium Symposium. Journal of Inorganic Biochemistry, 2009, 103, 473.	3.5	2
120	A novel vanadyl complex with a polypyridyl DNA intercalator as ligand: A potential anti-protozoa and anti-tumor agent. Journal of Inorganic Biochemistry, 2009, 103, 1386-1394.	<b>3.</b> 5	85
121	Electronic Properties of a Cytosine Decavanadate: Toward a Better Understanding of Chemical and Biological Properties of Decavanadates. Inorganic Chemistry, 2009, 48, 9742-9753.	4.0	37
122	Synthesis, Characterization, and Application of Vanadiumâ^Salan Complexes in Oxygen Transfer Reactions. Inorganic Chemistry, 2009, 48, 3542-3561.	4.0	181
123	Polystyrene bound oxidovanadium(IV) and dioxidovanadium(V) complexes of histamine derived ligand for the oxidation of methyl phenyl sulfide, diphenyl sulfide and benzoin. Dalton Transactions, 2009, , 2185.	3.3	47
124	Biospeciation of various antidiabetic VIVO compounds in serum. Dalton Transactions, 2009, , 2428.	3.3	109
125	Epoxidation of olefins catalysed by vanadium–salan complexes: a theoretical mechanistic study. Dalton Transactions, 2009, , 5460.	3.3	49
126	Polymer-bound oxidovanadium(IV) and dioxidovanadium(V) complexes: synthesis, characterization and catalytic application for the hydroamination of styrene and vinyl pyridine. Dalton Transactions, 2009, , 9555.	3.3	46

#	Article	IF	CITATIONS
127	Ethanolic Extract of Propolis (EEP) Enhances the Apoptosis- Inducing Potential of TRAIL in Cancer Cells. Molecules, 2009, 14, 738-754.	3.8	160
128	Membrane structure and interactions of a short Lycotoxin I analogue. Journal of Peptide Science, 2008, 14, 528-534.	1.4	18
129	Pyrazolyl–Diamine Ligands That Bear Anthracenyl Moieties and Their Rhenium(I) Tricarbonyl Complexes: Synthesis, Characterisation and DNAâ€Binding Properties. ChemBioChem, 2008, 9, 131-142.	2.6	42
130	A Polymer-Bound Oxidovanadium(IV) Complex Prepared from anL-Cysteine-Derived Ligand for the Oxidative Amination of Styrene. European Journal of Inorganic Chemistry, 2008, 2008, 577-587.	2.0	47
131	Vanadate substituted phytase: Immobilization, structural characterization and performance for sulfoxidations. Journal of Inorganic Biochemistry, 2008, 102, 318-329.	3 <b>.</b> 5	35
132	Immobilisation of oxovanadium(IV), dioxomolybdenum(VI) and copper(II) complexes on polymers for the oxidation of styrene, cyclohexene and ethylbenzene. Applied Catalysis A: General, 2008, 351, 239-252.	4.3	116
133	Biospeciation of antidiabetic VO(IV) complexes. Coordination Chemistry Reviews, 2008, 252, 1153-1162.	18.8	162
134	Oxidation of p-chlorotoluene and cyclohexene catalysed by polymer-anchored oxovanadium(iv) and copper(ii) complexes of amino acid derived tridentate ligands. Dalton Transactions, 2008, , 4220.	3.3	52
135	Vanadium Schiff Base Complexes: Chemistry, Properties, and Concerns about Possible Therapeutic Applications. ACS Symposium Series, 2007, , 340-351.	0.5	7
136	Complexation of Molybdenum(VI) with Bis(3-hydroxy-4-pyridinone)amino Acid Derivatives. European Journal of Inorganic Chemistry, 2007, 2007, 1728-1737.	2.0	19
137	Zeolite-Encapsulated Copper(II) Complexes of Pyridoxal-Based Tetradentate Ligands for the Oxidation of Styrene, Cyclohexene and Methyl Phenyl Sulfide. European Journal of Inorganic Chemistry, 2007, 2007, 5720-5734.	2.0	41
138	The N-terminal Half of the Peroxisomal Cycling Receptor Pex5p is a Natively Unfolded Domain. Journal of Molecular Biology, 2006, 356, 864-875.	4.2	76
139	X-ray Crystal Structure and Characterization in Aqueous Solution of{N,N′-Ethylenebis(pyridoxylaminato)}zinc(II). European Journal of Inorganic Chemistry, 2006, 2006, 656-662.	2.0	25
140	Water-Soluble Sal2en- and Reduced Sal2en-Type Ligands: Study of Their Cull and Nill Complexes in the Solid State and in Solution. European Journal of Inorganic Chemistry, 2006, 2006, 2819-2830.	2.0	46
141	Vanadium (IV and V) Complexes of Reduced Schiff Bases Derived from the Reaction of Aromatico-Hydroxyaldehydes and Diamines Containing Carboxyl Groups. European Journal of Inorganic Chemistry, 2006, 2006, 3595-3606.	2.0	19
142	Interactions of Insulin-Mimetic Vanadium Complexes with the Cell Constituents ATP and Glutathione. European Journal of Inorganic Chemistry, 2006, 2006, 3614-3621.	2.0	25
143	Preparation and characterisation of oxovanadium(IV) complexes derived from 2,6-diformyl-4-methylphenol and l-His and l-Ala. Spectroscopic study of the system VIVO2++BDF–His. Inorganica Chimica Acta, 2005, 358, 2246-2254.	2.4	8
144	Vanadium(IV andV) Complexes of Schiff Bases and Reduced Schiff Bases Derived from the Reaction of Aromatico-Hydroxyaldehydes and Diamines: Synthesis, Characterisation and Solution Studies. European Journal of Inorganic Chemistry, 2005, 2005, 732-744.	2.0	104

#	Article	IF	Citations
145	Novel Asymmetric Wittig Reaction: Synthesis of Chiral Allenic Esters ChemInform, 2005, 36, no.	0.0	0
146	Uptake and metabolic effects of insulin mimetic oxovanadium compounds in human erythrocytes. Journal of Inorganic Biochemistry, 2005, 99, 2328-2339.	3.5	65
147	Oxovanadium(iv) complexes of salicyl-l-aspartic acid and salicylglycyl-l-aspartic acid. Dalton Transactions, 2005, , 3072.	3.3	8
148	Interaction and Lipid-Induced Conformation of Two Cecropinâ^'Melittin Hybrid Peptides Depend on Peptide and Membrane Composition. Journal of Physical Chemistry B, 2005, 109, 17311-17319.	2.6	49
149	Micro-focused ultrasonic solid–liquid extraction (Î⅓FUSLE) combined with HPLC and fluorescence detection for PAHs determination in sediments: optimization and linking with the analytical minimalism concept. Talanta, 2005, 66, 1272-1280.	5.5	72
150	Enantioselectivity in Ni(ii) Schiff-base complexes derived from amino-acids and (S)-o-N-(N-benzylprolyl)aminobenzophenone. Molecular structure of several chiral Ni(ii) Schiff-base complexes, circular dichroism and molecular mechanics studies. Dalton Transactions, 2005, , 2312.	3.3	16
151	Novel Asymmetric Wittig Reaction: Synthesis of Chiral Allenic Esters. European Journal of Organic Chemistry, 2004, 2004, 4830-4839.	2.4	34
152	Bovine serum albumin conformational changes upon adsorption on titania and on hydroxyapatite and their relation with biomineralization. Journal of Biomedical Materials Research Part B, 2004, 70A, 420-427.	3.1	64
153	N,N′-Ethylenebis(pyridoxylideneiminato) andN,N′-Ethylenebis(pyridoxylaminato): Synthesis, Characterization, Potentiometric, Spectroscopic, and DFT Studies of Their Vanadium(IV) and Vanadium(V) Complexes. Chemistry - A European Journal, 2004, 10, 2301-2317.	3.3	127
154	Structural studies of decavanadate compounds with organic molecules and inorganic ions in their crystal packing. Inorganica Chimica Acta, 2004, 357, 4476-4487.	2.4	45
155	Solid state and solution studies of a vanadium(III)-l-cysteine compound and demonstration of its antimetastatic, antioxidant and inhibition of neutral endopeptidase activities. Journal of Inorganic Biochemistry, 2004, 98, 959-968.	3.5	68
156	N-Salicylideneamino acidato complexes of oxovanadium(iv). The cysteine and penicillamine complexes. Dalton Transactions, 2004, , 2855.	3.3	24
157	Investigation of the cytosine–decavanadate interaction from an experimental charge density: a supramolecular arrangement of Na3V10O28(C4N3OH5)3(C4N3OH6)3·10H2O in the solid state. Acta Crystallographica Section A: Foundations and Advances, 2004, 60, s34-s34.	0.3	0
158	Interaction of VIVO, VVO2 and Cull with a Peptide Analogue SalGly-L-Ala. European Journal of Inorganic Chemistry, 2003, 2003, 2113-2122.	2.0	15
159	Interactions of VO(IV) with oligopeptides. Coordination Chemistry Reviews, 2003, 237, 123-133.	18.8	49
160	Preparation and characterisation of vanadium complexes derived from salicylaldehyde or pyridoxal and sugar derivatives. Inorganica Chimica Acta, 2003, 356, 121-132.	2.4	37
161	Contribution to the synthesis of chiral allenic esters. Tetrahedron Letters, 2003, 44, 6409-6412.	1.4	10
162	VIVO and VVO2 complexes of schiff base derivatives of ethylenediamine and vitamine B6. Journal of Inorganic Biochemistry, 2003, 96, 211.	3.5	0

#	Article	IF	Citations
163	Synthesis of Chiral Pyrrolo[1,2-c]thiazoles via Intramolecular Dipolar Cycloaddition of Münchnones: An Interesting Rearrangement to Pyrrolo[1,2-c]thiazines. Journal of Organic Chemistry, 2002, 67, 4045-4054.	3.2	49
164	Oxovanadium(iv and v) and copper(ii) complexes of N-salicyl-glycylglycine and N-salicyl-glycylglycylglycine. Dalton Transactions RSC, 2002, , 4440.	2.3	17
165	Molecular modelling studies of N-salicylideneamino acidato complexes of oxovanadium(iv). Molecular and crystal structure of a new dinuclear LOVIV–O–VVOL mixed valence complex. Dalton Transactions RSC, 2002, , 4407.	2.3	72
166	Model investigations for vanadium-protein interactions: vanadium(III) compounds with dipeptides and their oxovanadium(IV) analogues. Journal of Biological Inorganic Chemistry, 2002, 7, 363-374.	2.6	25
167	In vitro study of the insulin-mimetic behaviour of vanadium(IV, V) coordination compounds. Journal of Biological Inorganic Chemistry, 2002, 7, 384-396.	2.6	220
168	The systems VIVO2+-glutathione and related ligands: a potentiometric and spectroscopic study. Journal of Biological Inorganic Chemistry, 2002, 7, 225-240.	2.6	49
169	Thiolate-S as anchoring donor in the binary and ternary VO(IV) complexes of mercaptopropionylglycine. Inorganica Chimica Acta, 2002, 339, 119-128.	2.4	32
170	The system VO2++oxidized glutathione: a potentiometric and spectroscopic study. Journal of Inorganic Biochemistry, 2001, 84, 259-270.	3.5	56
171	Preparation and characterisation of new oxovanadium(IV) Schiff base complexes derived from salicylaldehyde and simple dipeptides. Inorganica Chimica Acta, 2000, 305, 7-13.	2.4	37
172	Oxovanadium(IV) complexes with aromatic aldehydes. Journal of Inorganic Biochemistry, 2000, 80, 35-39.	3.5	55
173	Preparation and characterisation of new oxovanadium(IV) Schiff base complexes derived from amino acids and aromatic o-hydroxyaldehydes. Inorganica Chimica Acta, 1999, 293, 1-11.	2.4	88
174	Factors governing abundance of hydrolyzable amino acids in the sediments from the N.W. European Continental Margin (47–50°N). Progress in Oceanography, 1998, 42, 145-164.	3.2	59
175	X-ray characterization of an unusual product obtained from [VO(Sal–Phe)(H2O)] in H2Opyridine solutions. Polyhedron, 1998, 17, 3269-3274.	2.2	9
176	Oxovanadium(IV)-Promoted Peptide-Amide Deprotonation in Aqueous Solution. Inorganic Chemistry, 1998, 37, 6389-6391.	4.0	24
177	Oxovanadium(IV) complexes of the dipeptides glycyl-L-aspartic acid, L-aspartylglycine and related ligands; a spectroscopic and potentiometric study. Journal of the Chemical Society Dalton Transactions, 1998, , 3587-3600.	1.1	35
178	Preparation of [VO(sal-L-Trp)(H2O)] (sal-L-Trpâ€=â€N-salicylidene-L-tryptophanate) and characterisation of an unusual product obtained from its solutions in water–pyridine. Journal of the Chemical Society Dalton Transactions, 1998, , 4015-4020.	1.1	30
179	Oxovanadium(IV) complexes of peptides with non-co-ordinating side chains and related ligands; a spectroscopic study. Journal of the Chemical Society Dalton Transactions, 1997, , 569-576.	1.1	27
180	Monitoring the removal of soluble salts from ancient tiles by ion chromatography. Journal of Chromatography A, 1997, 770, 195-201.	3.7	14

#	Article	IF	CITATIONS
181	Removal and Analysis of Soluble Salts from Ancient Tiles. Studies in Conservation, 1996, 41, 153.	1.1	6
182	Molecular structure of [VO(sal-D,L-Asn)(py)(H2O)] and reaction to produce coumarin-3-carboxamide. Chemical Communications, 1996, , 1365.	4.1	32
183	Crystal and molecular structure of [V2O3(sal-L-val)2(H2O)](sal-L-val =N-salicylidene-L-valinate) and spectroscopic properties of related complexes. Journal of the Chemical Society Dalton Transactions, 1996, , 1989.	1.1	74
184	N-salicylideneamino-acidate complexes of oxovanadium(IV)â€"II. Synthesis, characterization and deamination of an n-salicylideneglycylglycinato complex. Polyhedron, 1995, 14, 429-439.	2.2	36
185	Oxovanadium(IV) and amino acidsâ€"VII. The system l-histidine+VO2+; a self-consistent potentiometric and spectroscopic study. Polyhedron, 1994, 13, 3177-3198.	2.2	21
186	N-salicylideneamino acidate complexes of oxovanadium(IV). Part 1. Crystal and molecular structures and spectroscopic properties. Journal of the Chemical Society Dalton Transactions, 1994, , 149.	1.1	58
187	Synthesis and structural characterization of a polyoxovanadate coordination complex [V4O8(CH3O)4(bipy)2] with a tetrametallate core. Polyhedron, 1993, 12, 1231-1237.	2.2	18
188	Oxovanadium(IV) and amino acidsâ€"VI. The systems glycylglycine and glycylglycylglycine + VO2+; a potentiometric and spectroscopic study. Polyhedron, 1993, 12, 2857-2867.	2.2	28
189	Salicylideneserinato complexes of vanadium. Crystal structure of the sodium salt of a complex of vanadium-(IV) and -(V). Journal of the Chemical Society Dalton Transactions, 1992, , 1745.	1.1	61
190	Oxovanadium(IV) and amino acidsî—, V. The system l-glutamic acid+VO2+; a potentiometric and spectroscopic study. Polyhedron, 1992, 11, 1449-1461.	2.2	24
191	The system l-malic acid+oxovanadium(IV); a potentiometric and spectroscopic study. Polyhedron, 1992, 11, 697-708.	2.2	16
192	Oxovanadium(IV) and amino acidsâ€"IV. The systems l-cysteine or d-penicillamine+VO2+; a potentiometric and spectroscopic study. Polyhedron, 1990, 9, 2101-2125.	2.2	29
193	Oxovanadium(IV) and amino acids—III. The system l-aspartic acid+vo2+; A potentiometric and spectroscopic study. Polyhedron, 1990, 9, 81-98.	2.2	34
194	Oxovanadium(IV) and amino acidsâ€"II. The systems l-serine and l-threonine+VO2+. A potentiometric and spectroscopic study. Polyhedron, 1989, 8, 1173-1199.	2.2	42
195	The systems l-cysteine and d-penicillamine+ oxovanadium(IV); a potentiometric and spectroscopic study. Polyhedron, 1989, 8, 1745-1747.	2.2	14
196	Oxovanadium(IV) and amino acidsâ€"I. The system L-alanine+VO2+; a potentiometric and spectroscopic study. Polyhedron, 1988, 7, 1245-1262.	2.2	62
197	Bis-(N-hydroxy-iminodiacetate)vanadate(IV), a synthetic model of â€~amavadin'. Journal of the Chemical Society Chemical Communications, 1988, , 1158-1159.	2.0	29